• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Infect Dis . Immunoglobulin glycosylation profiling for early identification of patients with severe influenza pneumonia

tetano

Editor, Senior Moderator
BMC Infect Dis


. 2025 Sep 26;25(1):1167.
doi: 10.1186/s12879-025-11538-6. Immunoglobulin glycosylation profiling for early identification of patients with severe influenza pneumonia

Fei Teng[SUP] 1 [/SUP], Dian-Geng Li[SUP] 2 [/SUP], Wen-Xin Liu[SUP] 1 [/SUP], Xin Liu[SUP] 1 [/SUP], Guang-Xu Liu[SUP] 3 [/SUP], Hao Wang[SUP] 4 [/SUP], Hui-Hua Li[SUP] 1 [/SUP], Min Zhang[SUP] 5 [/SUP], Shu-Bin Guo[SUP] 6 [/SUP]



Affiliations
Abstract

Background: Uncontrolled inflammation can result in severe status and even death in influenza patients, and there is a lack of early clinical evaluation models.
Methods: We recruited patients with influenza pneumonia and healthy controls from the emergency departments of three urban teaching hospitals in Beijing, China, during the winter of 2018-2019. Donated plasma samples were screened using protein and lectin microarrays to assess changes in the glycosylation patterns of immunoglobulins. These changes were used to develop and validate an Immunoglobulin Glycosylation Profile for Severe Status Identification Algorithm (IGPSSIA). A combined model of IGPSSIA score and clinical indicators was constructed to identify severe influenza pneumonia cases.
Results: We enrolled 114 patients, including 56 in the mild and 58 in the severe groups, and recruited 27 volunteers as healthy controls. We screened out the differentially expressed glycan moieties between the mild and the severe groups and included them in the LASSO regression analysis. In the training set (70% of patients, n = 80), IGPSSIA = 1.113 × [GNL‑IgG4 Man] - 2.499 × [LCA‑IgG1 Man] + 0.029 × [BanLec‑IgA2 Man] + 0.529 × [HHL, AL‑IgM Man] - 2.210 × [sWGA‑IgG GlcNAc] + 0.001 × [PSA‑IgG4 Man] + 0.027 × [Ricin B Chain‑IgG2 Gal & GalNAc]. Finally, we constructed a clinical diagnostic model using age, time interval from onset to admission, lymphocyte count, platelet count and IGPSSIA score, and achieved an AUC of 0.839 (95% CI 0.767-0.911).
Conclusions: Changes in immunoglobulin glycosylation profiles can be a promising tool for identifying severe status in patients with influenza pneumonia.

Keywords: Immunoglobulin glycosylation; Inflammation; Influenza; Lectin microarray.

 
Back
Top